Stable acquired resistance to etoposide (VP-16) or teniposide (VM- 26) in 11(1116 human colon carcinoma cells and A549 human lung adenocarcinoma cells, was previously obtained by weekly 1-h exposures to cither drug (B. H. Long, Nati. Cancer Inst. Monogr., 4: 123-127, 1987). The purpose of this study was to identify possible mechanisms of resistance present in these cells by using human nutrãand topoisomerase II DNA probes, antibodies to these gene products, and P4 phage unknotting assay for topoisomerase II activities. HCT116(VP)35 cells were 9-, 7-, and 6-fold resistant to VP-16, VM-26, and Adriamycin, respec tively, and showed no cross-resistance to colchicine and actinomycin D. These cells had no differences in mdrl gene, mdrl mRNA, or Pglycoprotein levels but displayed decreased levels of topoisomerase II mRNA and enzyme activity without any alteration of drug sensitivity displayed by the enzyme. HCT116(VM)34 cells were 5-, 7-, and 21-fold resistant to VP-16, VM-26, and Adriamycin; were cross-resistant to colchicine (7-fold) and actinomycin D (18-fold); and possessed a 9-fold increase in mdrl mRNA and increased P-glycoprotcin without evidence of mdrl gene amplification. No alterations in topoisomerase II gene or mRNA levels, enzyme activity, or drug sensitivity were observed. A549(VP)28 and A549(VM)28 cells were 8-fold resistant to VP-16 and VM-26 and 3-fold resistant to Adriamycin. Both lines were not crossresistant to colchicine or actinomycin D but were hypersensitive to ci.\- platinum. No alterations in mdrl gene, mdrl mRNA, or P-glycoprotein levels, but lower topoisomerase II mRNA levels and decreased enzyme activities, were observed. Of the four acquired resistant cell lines, resist ance is likely related to elevated imlrl expression in one line and to decreased topoisomerase II expression in the other three lines.
|Original language||English (US)|
|Number of pages||9|
|State||Published - Oct 1991|
ASJC Scopus subject areas
- Cancer Research